Strides Pharma Science announced that it has secured the approval of its equity shareholders and secured creditors with overwhelming majority, along with those of OneSource Specialty Pharma Limited and SteriScience Specialties, in meetings convened under the guidance of the National Company Law Tribunal (NCLT). All the secured creditors who voted on the scheme for the three companies in their respective meetings, were in favour of the Scheme. This is a critical step in the creation of OneSource and the support from shareholders and secured creditors underscores the confidence in the company’s strategic initiative to create OneSource as India’s first specialty pharma contract development and manufacturing organization (CDMO) covering advanced sectors like biologics, complex injectables, and oral technologies, including soft-gelatin capsules, said the company. In September 2023, Strides announced its strategic initiative to create OneSource as an independent specialty pharma CDMO by integrating the oral technologies (soft gelatin capsules) business from Strides, sterile injectables business of SteriScience Specialty Private Limited and the Biologics and high-end drug devices combination business of OneSource (erstwhile Stelis). Having already received Stock Exchange approvals in May 2024, this latest approval from equity shareholders and secured creditors marks a significant milestone. The company will now seek final approval from the NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE. Commenting on the development, Arun Kumar, executive chairperson and Badree Komandur, managing director and Group CEO, Strides Pharma Science stated, “We are pleased to have received the strong backing from our shareholders and secured creditors for the creation of OneSource. We believe OneSource will unlock considerable value for Strides' stakeholders upon its listing. We remain committed to delivering on this promise and express our gratitude to our shareholders and creditors for their continued trust and support.”
|